Loading…
CTOR
Citius Oncology Inc
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 17331Y109
$0.78-1.86%Price as of Aug 29, 18:47 UTC · updated once a day, after the close
Key metrics
- Market cap
- $82.03M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.48
- ROE
- -126.58%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 3.49
- 52-week high
- $2.25
- 52-week low
- $0.49
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -89.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.00 | $1.15 | $10.94 | $10.16 | |
| P/E | — | — | — | 40.5x | 84.7x |
| P/B | 1.9x | 1.9x | 1.8x | — | 262.9x |
| EPS | -$0.34 | -$0.31 | $0.27 | $0.12 | |
| ROE | -45.84% | -55.19% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZYBTZhengye Biotechnology Holding Ltd | $1.73 | — | 2.2x | — | -25.17% | $81.99M |
| ATHEAlterity Therapeutics Ltd | $4.51 | — | 0.0x | — | -47.02% | $81.75M |
| SERASERA Prognostics Inc | $2.07 | — | 1.4x | — | -45.03% | $81.66M |
| MAIAMAIA Biotechnology, Inc. | $1.33 |
About the company
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
- Cranford, United States
Company description provided by Yahoo Finance.